Diluted shares outstanding of Artivion, Inc. – HAN:CYL
This article provides financial information for Artivion, Inc. (HAN:CYL), specifically focusing on its diluted shares outstanding. The content is primarily a data placeholder from TradingView, indicating that specific value and change data for diluted shares outstanding would be displayed for various periods.
Total equity of Artivion, Inc. – HAN:CYL
The article focuses on the total equity information for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It indicates that the market was closed with no trades at the time of the report. The content also briefly lists the various data providers and copyright information relevant to the financial data presented.
Artivion, Inc. Statistics – HAN:CYL
This page provides financial statistics for Artivion, Inc. (CYL) traded on the Hannover Stock Exchange. It offers an overview of key financial ratios and metrics, including valuation, profitability, liquidity, solvency, and per-share metrics, with data available annually and quarterly from 2006 to 2025.
Basic earnings per share (basic EPS) of Artivion, Inc. – HAN:CYL
This article provides financial information for Artivion, Inc. (HAN:CYL) on the Hannover Stock Exchange, specifically focusing on its basic earnings per share (basic EPS). It presents an overview of the company's financials without detailed figures in the provided content. The piece highlights that the market for this stock is currently closed with no trades.
Artivion, Inc. Cash Flow – HAN:CYL
This article provides a financial overview of Artivion, Inc. (CYL) focusing on its cash flow activities. It highlights the free cash flow for Q2 2026 as -10.52M EUR, with 2025 figures for free cash flow at 714.34K EUR and operating cash flow at 33.95M EUR. The content is primarily a data presentation, indicating the company's financial performance in terms of operating, investing, and financing cash flows.
Artivion, Inc. Revenue Breakdown – NYSE:AORT
Artivion, Inc. (NYSE: AORT) reported a total revenue of $441.33 million USD last year. The Medical Devices segment was the top performer, contributing $345.82 million USD, an increase from $290.23 million USD the prior year. Geographically, the United States was the largest revenue generator, accounting for $214.07 million USD.
CCORF Maintains Artivion(AORT.US) With Buy Rating, Maintains Target Price $39
CCORF has reiterated its Buy rating for Artivion (AORT.US) and maintained a target price of $39. This suggests continued confidence in the company's performance and future outlook from the firm.
Artivion, Inc. (AORT) stock price, news, quote and history
Artivion, Inc. (AORT) stock showed a slight increase after hours, following a dip at market close on September 25th. The company, which specializes in medical devices and implantable human tissues, has seen significant price fluctuations over various periods. Analyst ratings indicate a strong buy consensus with a target price of $42.15.
AMDS Approval Could Be A Big Test For Artivion Stock (AORT)
Artivion (AORT) recently reported 11% Q2 2026 revenue growth but a net loss of US$13.5 million, despite securing FDA approval for its AMDS Hybrid Prosthesis and completing the Endospan acquisition. The company now boasts a complete aortic arch portfolio, but full-year revenue guidance reiteration highlights ongoing cost and profitability challenges. The investment narrative hinges on whether new products like AMDS can drive profitability and physician adoption without further margin erosion.
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
Artivion Inc. (AORT) reported strong Q2 2026 revenue growth of 11% and completed its aortic arch portfolio, yet simultaneously posted a net loss of $13.5 million, a significant reversal from the previous year's profit. The company's acquisitions and FDA approvals, while bolstering its product lineup, are currently impacting profitability, leading to a reiterated rather than raised full-year guidance. This divergence between revenue growth and widening losses is creating uncertainty for investors, with a notable pullback in hedge fund holdings.
Artivion’s (AORT) Growth Story Hides A Widening Bottom-Line Problem
Artivion Inc. reported strong revenue growth of 11% in Q2 2026, driven by key acquisitions and FDA approvals for its aortic arch portfolio. However, this growth was overshadowed by a significant net loss of $13.5 million, a reversal from a profit in the prior year, and a decline in non-GAAP net income. The article highlights the challenge for investors to reconcile the company's expanding product line with its deteriorating profitability, as institutional conviction shows a slight pullback and the forward P/E suggests market uncertainty regarding its earnings recovery.
Artivion SVP Andrew Green sells $286k in company shares By Investing.com
Artivion's Senior Vice President of Regulatory and Quality, Andrew M. Green, sold 11,480 shares of company stock for a total of $286,655 on September 10, 2026. This insider sale occurred as Artivion's stock has declined 45% year-to-date and is considered overvalued by InvestingPro analysis, despite analysts predicting profitability this year and the company reporting strong Q2 revenue.
Artivion SVP Andrew Green sells $286k in company shares
Andrew M. Green, SVP of Regulatory and Quality at ARTIVION, INC. (NASDAQ:AORT), sold 11,480 shares for $286,655 on September 10, 2026, retaining 40,160 shares. This transaction occurred as the stock declined 45% year-to-date, trading at $25.08. Separately, Artivion reported strong Q2 revenues exceeding forecasts and received a raised price target from Canaccord Genuity following recent acquisitions and growth.
Artivion SVP Andrew Green sells $286k in company shares By Investing.com
Andrew M. Green, Senior Vice President at ARTIVION, INC. (NASDAQ:AORT), sold 11,480 shares of company stock for a total of $286,655. This transaction occurred as Artivion's stock has declined 45% year-to-date and is considered overvalued by InvestingPro analysis, despite analyst predictions of profitability this year. The company recently reported strong Q2 revenue, exceeding Wall Street forecasts, and had its price target raised by Canaccord Genuity.
Planned insider stock sales at Artivion (NYSE: AORT) raise a new question: how many shares could be sold this time?
An Artivion, Inc. officer, Andrew M. Green, has filed a Rule 144 notice indicating planned sales of 11,480 common shares tied to compensation vesting and previous 2026 sales. The filing details prior sales by Green and outlines upcoming share vestings in February 2026. Fidelity Brokerage Services LLC is managing these transactions as attorney-in-fact for Mr. Green.
Artivion Inc (AORT) Insider Sell: SVP, Regulatory and Quality Andrew Green Disposes of 8,003 Shares
Andrew Green, SVP of Regulatory and Quality at Artivion Inc (AORT), sold 8,003 shares of the company on September 3, 2026, totaling approximately $216,321. This sale contributes to a pattern of 45 insider sells and zero buys at Artivion over the past year. While GuruFocus's GF Value indicates the stock is modestly undervalued, the consistent insider selling suggests caution for investors despite the valuation signal.
Artivion SVP Andrew Green sells $216k in stock By Investing.com
Andrew M. Green, Senior Vice President of Regulatory and Quality at ARTIVION, INC. (NASDAQ:AORT), sold $216,337 worth of company common stock in early September 2026 across two transactions. Following these sales, Mr. Green directly holds 51,640 shares. Artivion recently reported strong Q2 revenue and adjusted EBITDA, exceeding analyst forecasts, and received a raised price target from Canaccord Genuity.
Artivion (NYSE: AORT) insider logged a 44,001-share sale and now plans more trades
Artivion (AORT) officer Andrew M. Green has filed a Rule 144 notice to sell 1,493 shares of common stock, valued at $38,842.13, through Fidelity Brokerage Services LLC. These shares are linked to restricted stock awards vesting in November 2025 and February 2026. The filing also revealed that Green previously sold 44,001 shares for $910,753.51 on June 11, 2026, and additional shares in August and September 2026.
Trading the Move, Not the Narrative: (AORT) Edition
This article provides an AI-driven analysis for Artivion Inc Com (NASDAQ: AORT), highlighting near-term weak sentiment and an exceptional 89.1:1 risk-reward setup. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels, alongside a multi-timeframe signal analysis. The report suggests potential for long-term weakness resumption after a neutral shift and emphasizes a mid-channel oscillation pattern.
Artivion (AORT) Stock Looks Cheap On Cash Flow But Pricey On Sales
Artivion (AORT) stock has seen a 57.6% gain over three years, but current valuations suggest it's close to its intrinsic value, not a clear bargain. Both Discounted Cash Flow (DCF) and price-to-sales (P/S) models indicate the stock is broadly in line with fundamentals, with the DCF showing only a 1.5% discount and the P/S ratio being slightly above the model's fair range. The article concludes that the stock's future performance hinges on consistent execution and cash generation to justify its current pricing, as there's little valuation buffer for disappointment.
Have Artivion Insiders Been Selling Stock?
Artivion (NYSE:AORT) recently saw its Chairman, James Mackin, sell approximately US$2.0m worth of shares, reducing his holding by 7.4%. While this was the largest insider sale in the last year, insiders still maintain 5.1% ownership, valued at US$70m. The article notes that there have been no insider purchases in the last year, suggesting caution for potential investors.
Insider Selling: Artivion (NYSE:AORT) CEO Sells $2,026,500.00 in Stock
Artivion's CEO, James Mackin, sold 70,000 shares of company stock for $2.03 million, reducing his ownership by 7.39%. This transaction follows the company's recent earnings report where it exceeded revenue expectations with $125.76 million. Despite the insider selling, analysts maintain a "Moderate Buy" rating for AORT, with an average price target of $44.83.
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion, Inc. reported increased revenue for Q2 2026 and H1 2026, but also experienced a swing from net income to net losses. This shift raises questions about the company's ability to convert revenue growth into sustainable profits, despite the recent FDA approval for its AMDS product, which represents a significant market opportunity. The article suggests investors consider multiple future scenarios for Artivion, given its growing debt and recent unprofitability.
Artivion (NASDAQ: AORT) executive moves to sell 70,000 shares
Artivion (NASDAQ: AORT) officer James P. Mackin has filed a Form 144 notice to sell up to 70,000 shares of common stock, with an aggregate market value of $2,053,100.00. The shares, originally compensation for services, are intended to be sold through Fidelity Investments on the NYSE. The filing indicates a neutral impact and sentiment on the company's stock.
Does Revenue Growth Amid New Losses Reshape The Bull Case For Artivion (AORT)?
Artivion (AORT) reported increased second-quarter 2026 revenue but a shift from net income to a net loss, raising questions about its investment narrative. While the FDA approval for its AMDS product in a significant market segment supports growth, the company faces challenges with rising costs, debt, and the need to convert regulatory success into profitable sales. The article examines how the revenue growth amid new losses affects Artivion's future outlook and current valuation.
Summit Creek Advisors LLC Takes Position in Artivion, Inc. $AORT
Summit Creek Advisors LLC has acquired a new stake of 120,354 shares in Artivion, Inc. worth approximately $2.7 million, representing a 0.25% ownership. Institutional investors and hedge funds now collectively own 86.37% of the company, which maintains a "Moderate Buy" consensus rating from analysts with an average price target of $44.83. Artivion recently exceeded revenue expectations, reporting $125.76 million against an estimate of $119.99 million, and earnings of $0.13 per share.
Canaccord raises Artivion stock price target to $40 on model update
Canaccord Genuity has increased its price target for Artivion Inc. (NYSE:AORT) to $40 from $39, maintaining a Buy rating. This adjustment follows a model update reflecting additional data from the company's Q2 10-Q filing and a change in the comparable company group multiple. Artivion recently reported strong Q2 revenues and adjusted EBITDA, exceeding analyst forecasts, and has received PMA approval for AMDS and completed the acquisition of Endospan.
Artivion SVP Andrew Green sells $17,586 of common stock
Artivion (AORT) SVP Andrew M. Green sold $17,586 worth of common stock on August 14, 2026, consisting of 616 shares at $28.549 each. This was a non-discretionary transaction to cover tax withholding obligations from vested restricted stock units. Following the sale, Green directly holds 59,643 shares, while the company has recently reported strong Q2 earnings, exceeding analyst forecasts, and received a raised price target from Canaccord.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of Artivion, Inc. (NASDAQ:AORT), sold 715 shares of common stock for $20,412 on August 14, 2026, to cover tax withholding obligations. This transaction is considered a "sell to cover" and not a discretionary sale, with Berry retaining 210,112 shares. Artivion recently reported strong Q2 2026 revenue of $125.8 million, surpassing forecasts, and Canaccord raised its price target for the company to $39.
Artivion EVP, COO, CFO & treasurer Berry sells $20,412 in stock
Lance A. Berry, EVP, COO, CFO, and Treasurer of ARTIVION, INC. (NASDAQ:AORT), sold 715 shares of common stock totaling $20,412 on August 14, 2026, to cover tax withholding obligations. Following the transaction, Berry directly holds 210,112 shares. Separately, Artivion reported strong Q2 revenue and adjusted EBITDA, surpassing analyst expectations, and received a raised price target from Canaccord.
Artivion CFO Lance A. Berry Sells 715 Shares to Cover RSU Tax Withholding
Artivion's CFO, Lance A. Berry, sold 715 shares of the company's common stock on August 14, 2026, at $28.549 per share. This transaction was not discretionary but was executed as a "sell to cover" to meet tax withholding obligations arising from the vesting of restricted stock units. Following this sale, Berry directly holds 210,112 shares of Artivion common stock.
Artivion SVP Andrew Green sells $17,586 of common stock
Andrew M. Green, SVP of Regulatory and Quality at ARTIVION, INC. (AORT), sold 616 shares of common stock totaling $17,586 on August 14, 2026, to cover tax withholding obligations. This non-discretionary sale occurred while ARTIVION shares showed an 11% return over the past week. The company also reported strong Q2 revenues, exceeding forecasts, and maintained its fiscal 2026 guidance, receiving a raised price target from Canaccord.
Artivion (NYSE: AORT) exec’s 616-share sale is tax-driven
Artivion executive Andrew M. Green, SVP, Regulatory and Quality, sold 616 shares of common stock at $28.549 per share on August 14, 2026. This transaction was a "sell to cover" to satisfy tax withholding obligations upon the vesting of restricted stock units and was not a discretionary trade. Following the sale, Green directly holds 59,643 shares of ARTIVION common stock.
Artivion (NYSE:AORT) Rating Lowered to Sell at Wall Street Zen
Wall Street Zen has downgraded Artivion (NYSE:AORT) from "hold" to "sell," though other analysts maintain a "Moderate Buy" consensus with an average target price of $44.67. The company recently exceeded revenue estimates, reporting $125.76 million against a $119.99 million consensus, with quarterly EPS of $0.13. Artivion's stock opened at $29.22, and recent insider transactions show share sales by senior vice presidents.
ARTIVION, INC. SEC Filing (Aug 14, 2026)
This article details an SEC Form 144 filing by Artivion, Inc. (AORT) on August 14, 2026, which indicates a proposed sale of 715 shares of common stock acquired through restricted stock vesting. The filing was accepted by the SEC at 3:59 PM on the same date and outlines the transaction details including the broker, market value, and date of acquisition.
Artivion (AORT): Nomura entities report 6.5% beneficial stake in 13G/A
Nomura Asset Management International Inc. and Nomura Investment Management Business Trust have reported a combined 6.5% beneficial ownership in Artivion, Inc., totaling 3,184,974 shares of common stock. This filing, a Schedule 13G/A, indicates shared voting and dispositive power over these shares, calculated based on 48,692,000 outstanding shares as of June 30, 2026. The report emphasizes transparency regarding significant ownership stakes in publicly traded companies.
Artivion SVP Jean Holloway sells 977 shares for $27,834
Artivion's Senior Vice President, Jean F. Holloway, sold 977 shares of company stock for $27,834, with each share priced at $28.49. This transaction leaves her with 184,118 directly held shares. Despite the stock appearing overvalued according to InvestingPro, analysts maintain price targets between $38 and $48, and the company recently reported strong Q2 revenues and raised guidance.
Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed
Artivion (AORT) shares rose 5.5% following FDA approval for its AMDS hybrid prosthesis and reaffirmed 2026 revenue guidance of approximately US$488 million. Despite a recent shift to a net loss from a net income in Q2 2026, the company's revenue outperformance and strategic product additions like AMDS and the NEXUS system are key drivers for its future growth. The FDA approval of AMDS is particularly significant as it targets an estimated US$150 million U.S. market and is central to the company's current catalyst stack, potentially influencing product mix and margin potential.
Artivion SVP Jean Holloway sells 977 shares for $27,834
Jean F. Holloway, SVP at Artivion Inc. (NASDAQ:AORT), sold 977 shares for $27,834 at $28.49 per share. This transaction occurred after the stock saw a 9.4% gain over the past week, and Holloway now directly holds 184,118 shares. The company recently reported strong Q2 revenue and adjusted EBITDA, leading Canaccord to raise its price target to $39.
Jean Holloway Sells 977 Shares of Artivion (NYSE:AORT) Stock
Jean Holloway, SVP of Artivion (NYSE:AORT), sold 977 shares of the company's stock for a total of $27,834.73, reducing her direct ownership to 184,118 shares. This transaction occurred as Artivion reported strong quarterly earnings, exceeding revenue estimates, and maintains a "Moderate Buy" consensus rating from analysts.
Artivion (AORT) Is Up 5.5% After FDA AMDS Approval And Reaffirmed 2026 Revenue Guidance - What's Changed
Artivion (AORT) stock rose by 5.5% following FDA approval for its AMDS hybrid prosthesis and the reaffirmation of its 2026 revenue guidance. The company reported increased revenue but a shift to a net loss in Q2 2026. This approval for AMDS is considered a key catalyst for Artivion, aiming to drive revenue growth and potentially narrow losses, despite short-term earnings volatility and reliance on complex, high-priced devices.
Artivion, Inc. (AORT) Stock Analysis: Strong Buy Ratings Signal Potential Upside of Nearly 60%
Artivion, Inc. (AORT), a healthcare sector player specializing in medical devices and implantable human tissues, shows promising growth potential despite recent market fluctuations. Analysts have given it strong "Buy" ratings with an average target price of $42.03, suggesting a nearly 60% upside from its current trading price of $26.31. While the company has areas for improvement in profitability metrics, its impressive revenue growth, healthy free cash flow, and strategic market positioning make it an intriguing opportunity for investors looking for long-term growth.
Artivion (AORT) Revenue Rose As Losses Emerged, Is It Still 37% Below Fair Value?
Artivion (AORT) recently reported Q2 2026 results showing increased revenue but a shift to losses. Despite a year-to-date share price decline, the company's valuation narrative suggests it is 37.4% undervalued, with a fair value of $42. This undervaluation hinges on continued regulatory approvals, new product launches, and geographical expansion.
Artivion revenue up 11% to USD 125.8M in Q2 2026
Artivion, Inc. reported an 11% increase in total revenues to $125.8 million for Q2 2026, driven by strong growth in On-X and stent grafts. The company also announced the acquisition of Endospan Ltd. and U.S. FDA approval for its AMDS Hybrid Prosthesis, strengthening its aortic arch portfolio. Artivion is reiterating its full-year 2026 revenue guidance of $480 to $496 million and adjusted EBITDA of $92 to $99 million.
Artivion (AORT) Stock Can Revenue Growth Outrun Fresh Losses?
Artivion (AORT) saw its stock edge up slightly despite a mixed Q2 2026 earnings report, which showed strong revenue growth but a swing back to a net loss. The company's aortic franchise, particularly with AMDS approval and growth in On X valves, fuels the bull case, while bears focus on margin compression, negative free cash flow, and execution risks from increased spending. Investors are weighing the potential for revenue growth against the immediate profitability challenges.
Canaccord raises Artivion stock price target on acquisition, PMA approval
Canaccord raised its price target for Artivion Inc. (NYSE:AORT) to $39 from $36, maintaining a Buy rating, following the company's acquisition of Endospan and PMA approval for AMDS. Artivion's second-quarter revenue of $125.8 million and adjusted EBITDA of $26.4 million both surpassed analyst estimates, driven by strong growth in On-X and Aortic Stent Grafts. The company reiterated its fiscal 2026 guidance, with net income expected to grow and commercialization of the NEXUS product in the U.S. anticipated to begin in 2027.
ARTIVION, INC. 2026: Revenue $125.76M, EPS ($0.28) — 10-Q Summary
ARTIVION, INC. (AORT) reported its quarterly results for 2026, with revenue increasing by 11.3% year-over-year to $125.76M. Despite the revenue growth, the company recorded a net loss of ($13.51M) and diluted EPS of ($0.28), a significant decrease from the prior year's net income. Key drivers for revenue growth included aortic stent grafts, On-X products, and preservation services, along with strategic acquisitions and accelerated adoption of new medical devices.
Q2 2026 Artivion Inc Earnings Call Transcript
Artivion Inc. (NYSE: AORT) recently held its Q2 2026 earnings call, detailing strong performance including FDA approval for its AMDS hybrid prosthesis and the acquisition of Endospan. The company reported significant growth in stent graft and ONIX revenues, and reiterated its full-year 2026 guidance, expecting 7-11% constant currency revenue growth and $92-99 million in adjusted EBITDA, despite a decrease in adjusted EBITDA margin and negative free cash flow due to investments and acquisition costs. Management expressed confidence in future growth while acknowledging some challenges like the delayed US launch of Nexus and variability in BioGlue revenue.
Artivion, Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AORT) 2026-08-07
Artivion, Inc. (AORT) released its 2026 Q2 earnings call presentation. The company reported an EPS of $0.13, beating estimates by $0.03, and revenue of $125.76 million, an 11.32% year-over-year increase, beating estimates by $5.74 million. This article provides access to the slide deck published in conjunction with these results.
Is Artivion Inc (AORT) Undervalued Despite $125.8 Million Revenue in Q2? GF Score: 82/100
Artivion Inc (AORT) reported Q2 2026 revenues of $125.8 million, an 11% year-over-year increase, exceeding analyst estimates, yet posted a net loss of $13.5 million. Despite the loss, driven partly by foreign currency revaluation and increased operating expenses, the company strengthened its product portfolio with FDA approval and an acquisition. GuruFocus assesses AORT as undervalued with a GF Score of 82/100 and a 6.8% upside potential, noting strong growth but average financial strength and profitability.
